Learn what retatrutide is, how this next‑generation triple agonist (GLP‑1, GIP, and glucagon) works for weight loss, obesity, and metabolic health, and see key phase 2 clinical trial results on body‑weight reduction and cardiometabolic benefits.
Discover how tirzepatide, a dual GIP and GLP‑1 receptor agonist, is redefining metabolic medicine with powerful HbA1c reductions and unprecedented weight loss results in obesity and type 2 diabetes clinical trials.
Discover how tirzepatide, a dual GIP and GLP-1 receptor agonist, delivers powerful glucose control and bariatric-level weight loss through smart peptide engineering, albumin binding, and protease resistance in modern metabolic medicine.
Learn how tirzepatide works as a dual GIP and GLP‑1 receptor agonist, why it’s different from traditional GLP‑1 drugs, and what clinical trials like SURMOUNT‑1 and SURPASS show for weight loss and type 2 diabetes control.
Discover why tirzepatide is more than “another GLP‑1.” Learn how its dual GIP/GLP‑1 agonism, advanced peptide engineering, and once‑weekly dosing deliver deeper glucose control, powerful weight loss, and broad metabolic benefits compared to traditional GLP‑1 drugs.
Discover how orforglipron, a first‑in‑class oral GLP‑1 receptor agonist, delivers injectable‑level weight loss and glycemic control in a once‑daily pill, with phase 2 data in obesity and type 2 diabetes.